Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kohn Website

Kurt W. Kohn, M.D., Ph.D.

Selected Publications

1)  Kohn KW, Zeeberg BM, Reinhold WC, Pommier Y.
Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype.
PLoS ONE. 9: e99269, 2014.
2)  Reinhold WC, Varma S, Sousa F, Sunshine M, Abaan OD, Davis SR, Reinhold SW, Kohn KW, Morris J, Meltzer PS, Doroshow JH, Pommier Y.
NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses.
PLoS ONE. 9: e101670, 2014.
3)  Fried JY, van Iersel MP, Aladjem MI, Kohn KW, Luna A.
PathVisio-Faceted Search: An Exploration Tool for Multi-Dimensional Navigation of Large Pathways.
Bioinformatics. 29: 1465-6, 2013.
4)  Luna A, Aladjem MI, Kohn KW.
SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism.
Genome Integr. 4: 6, 2013.
5)  Solier S, Ryan MC, Martin SE, Varma S, Kohn KW, Liu H, Zeeberg BR, Pommier Y.
Transcription poisoning by Topoisomerase I is controlled by gene length, splice sites, and miR-142-3p.
Cancer Res. 73: 4830-9, 2013.
6)  Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y.
CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set.
Cancer Res. 72: 3499-511, 2012.
7)  Zeeberg BR, Kohn KW, Kahn A, Larionov V, Weinstein JN, Reinhold W, Pommier Y.
Concordance of Gene Expression and Functional Correlation Patterns across the NCI-60 Cell Lines and the Cancer Genome Atlas Glioblastoma Samples.
PLoS ONE. 7: e40062, 2012.
8)  Solier S, Kohn KW, Scroggins B, Xu W, Trepel J, Neckers L, Pommier Y.
Feature Article: Heat shock protein 90alpha (HSP90alpha), a substrate and chaperone of DNA-PK necessary for the apoptotic response.
Proc Natl Acad Sci U S A. 109: [12866-72, 2012.
9)  Zeeberg BR, Reinhold W, Snajder R, Thallinger GG, Weinstein JN, Kohn KW, Pommier Y.
Functional categories associated with clusters of genes that are co-expressed across the NCI-60 cancer cell lines.
PLoS ONE. 7: e30317, 2012.
10)  Kohn KW, Zeeberg BR, Reinhold WC, Sunshine M, Luna A, Pommier Y.
Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processes.
PLoS ONE. 7: e35716, 2012.
11)  Chandan K, van Iersel MP, Aladjem MI, Kohn KW, Luna A.
PathVisio-Validator: a rule-based validation plugin for graphical pathway notations.
Bioinformatics. 28: 889-90, 2012.
12)  Luna A, Karac EI, Sunshine M, Chang L, Nussinov R, Aladjem MI, Kohn KW.
A Formal MIM Specification and Tools for the Common Exchange of MIM Diagrams: an XML-Based Format, an API, and a Validation Method.
BMC Bioinformatics. 12: 167, 2011.
13)  Luna A, Sunshine ML, van Iersel MP, Aladjem MI, Kohn KW.
PathVisio-MIM: PathVisio plugin for creating and editing Molecular Interaction Maps (MIMs).
Bioinformatics. 27: 2165-6, 2011.
14)  Solier S, Barb J, Zeeberg BR, Varma S, Ryan MC, Kohn KW, Weinstein JN, Munson PJ, Pommier Y.
Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors.
Cancer Res. 70: 8055-65, 2010.
15)  Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, Pommier Y, Reinhold WC.
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.
Mol. Cancer Ther. 9: 1080-91, 2010.
16)  Kim S, Aladjem MI, McFadden GB, Kohn KW.
Predicted functions of MdmX in fine-tuning the response of p53 to DNA damage.
PLoS Comput. Biol. 6: e1000665, 2010.
17)  Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, Douarre C, Conti C, Nakamura AJ, Das BB, Nicolas E, Kohn KW, Bonner WM, Pommier Y.
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks.
EMBO Rep. 10: 887-93, 2009.
18)  Solier S, Sordet O, Kohn KW, Pommier Y.
Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways.
Mol. Cell. Biol. 29: 68-82, 2009.
19)  Kohn KW, Aladjem MI, Weinstein JN, Pommier Y.
Network architecture of signaling from uncoupled helicase-polymerase to cell cycle checkpoints and trans-lesion DNA synthesis.
Cell Cycle. 8: 2281-99, 2009.
20)  Kohn KW, Aladjem MI, Weinstein JN, Pommier Y.
Chromatin Challenges during DNA Replication: A Systems Representation.
Mol. Biol. Cell. 19: 1-7, 2008.
21)  Meng LH, Kohn KW, Pommier Y.
Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288).
Oncogene. 26: 4806-16, 2007.
22)  Brazhnik P, Kohn KW.
HAUSP-regulated switch from auto- to p53 ubiquitination by Mdm2 (in silico discovery).
Mathematical biosciences. 210: 60-77, 2007.
23)  Miao ZH, Rao VA, Agama K, Antony S, Kohn KW, Pommier Y.
4-nitroquinoline-1-oxide induces the formation of cellular topoisomerase I-DNA cleavage complexes.
Cancer Res. 66: 6540-5, 2006.
24)  Marchand C, Antony S, Kohn KW, Cushman M, Ioanoviciu A, Staker BL, Burgin AB, Stewart L, Pommier Y.
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Mol. Cancer Ther. 5: 287-95, 2006.
25)  Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC.
Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma.
Cancer Res. 66: 7216-7224, 2006.
26)  Pommier Y, Weinstein JN, Aladjem MI, Kohn KW.
Chk2 molecular interaction map and rationale for Chk2 inhibitors.
Clin. Cancer Res. 12: 2657-61, 2006.
27)  Kohn KW, Aladjem MI.
Circuit diagrams for biological networks.
Mol. Syst. Biol. 2: 2006.0002, 2006.
28)  Kohn KW, Aladjem MI, Kim S, Weinstein JN, Pommier Y.
Depicting combinatorial complexity with the molecular interaction map notation.
Mol. Syst. Biol. 2: 51, 2006.
29)  Miao ZH, Agama K, Sordet O, Povirk L, Kohn KW, Pommier Y.
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes.
DNA Repair (Amst.). 5: 1489-94, 2006.
30)  Kohn KW, Aladjem MI, Weinstein JN, Pommier Y.
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology.
Mol. Biol. Cell. 17: 1-13, 2006.
31)  Furuta T, Hayward RL, Meng L, Takemura H, Aune G, Bonner W, Aladjem M, Kohn K, Pommier Y.
p21(CDKN1A) allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine.
Oncogene. Publication ahead of print, 2006.
32)  Kohn KW, Pommier Y.
Molecular interaction map of the p53 and Mdm2 logic elements, which control the Off-On switch of p53 in response to DNA damage.
Biochem Biophys Research Comm. 331: 816-827, 2005.
33)  Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW.
Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.
Curr. Pharm. Des. 11: 2855-72, 2005.
34)  Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW.
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks.
Oncogene. 23: 2934-49, 2004.
35)  Aladjem MI, Pasa S, Parodi S, Weinstein JN, Pommier Y, Kohn KW.
Molecular interaction maps--a diagrammatic graphical language for bioregulatory networks.
Sci STKE. 2004: pe8, 2004.
36)  Kohn KW, Riss J, Aprelikova O, Weinstein JN, Pommier Y, Barrett JC.
Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system.
Molec. Biol. Cell. 15: 3042-3052, 2004.
37)  Pommier Y, Kohn KW.
[Cell cycle and checkpoints in oncology: new therapeutic targets].
Med Sci (Paris). 19: 173-86, 2003.
38)  Sordet O, Khan QA, Kohn KW, Pommier Y.
Apoptosis induced by topoisomerase inhibitors.
Curr Med Chem Anti-Canc Agents. 3: 271-90, 2003.
39)  Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN.
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
Cancer Res. 63: 1000-11, 2003.
40)  Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN, Pommier Y.
Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Cancer Res. 63: 2782-93, 2003.
41)  Strumberg D, Nitiss JL, Dong J, Walker J, Nicklaus MC, Kohn KW, Heddle JG, Maxwell A, Seeber S, Pommier Y.
Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Antimicrob Agents Chemother. 46: 2735-46, 2002.
42)  Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN.
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
Cancer Res. 62: 1688-95, 2002.
43)  Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y.
UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
Cancer Res. 62: 5743-8, 2002.
44)  Kohn KW.
Molecular interaction maps as information organizers and simulation guides.
Chaos. 11: 84-97, 2001.
45)  Fan Y, Shi LM, Kohn KW, Pommier Y, Weinstein JN.
Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.
J Med Chem. 44: 3254-63, 2001.
46)  Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN.
A gene expression database for the molecular pharmacology of cancer.
Nat Genet. 24: 236-44, 2000.
47)  Orr MS, O'Connor PM, Kohn KW.
Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells.
J Natl Cancer Inst. 92: 987-94, 2000.
48)  Kohn KW, Shao RG, Pommier Y.
How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair?.
Cell Biochem Biophys. 33: 175-80, 2000.
49)  Kohn KW, Pommier Y.
Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors.
Ann N Y Acad Sci. 922: 11-26, 2000.
50)  Kohn KW, Andoh T.
Symposium: downstream from topoisomerase-DNA lesions: life-or-death consequences for the cell.
Cell Biochem Biophys. 33: 171-3, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/12/2014.